Regulatory and other responses to the pharmaceutical opioid problem

Thomas Polasek, Melody Caramins and Graeme Suthers
Med J Aust 2019; 211 (5): . || doi: 10.5694/mja2.50297
Published online: 2 September 2019

To the Editor: We read with interest the article regarding Australia's approach to managing the challenges of pharmaceutical opioid utilisation.1 The various regulatory, service delivery and educational activities described would appear to provide a comprehensive response to this problem. However, we were surprised to note the absence of any reference to the potential of pharmacogenomics in identifying patients at increased risk of opioid toxicity.

  • Thomas Polasek1,2
  • Melody Caramins3,4
  • Graeme Suthers3,5

  • 1  Certara, Princeton, NJ, USA
  • 2 Centre for Medicine Use and Safety, Monash University, Melbourne, VIC
  • 3 Royal College of Pathologists of Australasia, Sydney, NSW
  • 4 Healius, Sydney, NSW
  • 5 Sonic Healthcare, Sydney, NSW

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.